- Molecular NameLovastatin
- Synonym6 alpha-Methylcompactin; lovastatin; Lovastatina [Spanish]; Lovastatine [French]; Lovastatinum [Latin]
- Weight404.547
- Drugbank_IDDB00227
- ACS_NO75330-75-5
- Show 3D model
- LogP (experiment)4.26
- LogP (predicted, AB/LogP v2.0)4.2
- pkaN/A
- LogD (pH=7, predicted)4.2
- Solubility (experiment)0.0004 mg/mL
- LogS (predicted, ACD/Labs)(ph=7)-4.56
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds7
- TPSA72.83
- StatusFDA approved
- AdministrationN/A
- PharmacologyA member of the drug class of statins, used for lowering cholesterol (hypolipidemic agent) in those with hypercholesterolemia and so preventing cardiovascular disease.
- Absorption_value10.0
- Absorption (description)Lovastatin is absorbed after oral administration (30%)
- Caco_2N/A
- Bioavailability5.0
- Protein binding95.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP3A substrate). Hydrolysed in the liver to the active β-hydroxyacid form. Three other metabolites have also been detected: 3-hydroxy, 3-hydroxymethyl and 3-exomethylene derivatives. The drug undergoes extensive first-pass metabolism with less than 5% of a dose reaching circulation. Peak plasma concentrations are reached within 2 to 4 h and steady state within 2 to 3 days.
- Half life1~4 h
- ExcretionLovastatin is mainly excreted in faeces (85% of an administered dose) and 10% in urine over 72 h. It crosses the blood–brain and placental barriers.
- Urinary Excretion10
- Clerance4.3~18.3 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A